Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246421 | 0.85 | ALDH1A1 (0.74) | ALDH1A1MAPTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL3809960 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL10867494 | 0.84 | ALDH1A1 (0.76) | ALDH1A1MAPTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL10925574 | 0.82 | MAPT (0.85) | ALDH1A1MAPTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL243350 | 0.81 | MAPT (0.67) | ALDH1A1MAPTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL653579 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2KMT2ARAB9A | |
| 3-Methylbutanoic Acid SCHEMBL3359773 | 0.77 | AKR1B1 (0.57) | ALDH1A1MAPTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL11087760 | 0.76 | MAPT (0.67) | ALDH1A1MAPTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL11090808 | 0.75 | MAPT (0.66) | ALDH1A1MAPTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL246197 | 0.75 | ALDH1A1 (0.56) | ALDH1A1MAPTSMN1; SMN2RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000195-B2 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA, S.A.U. (ES) | 2015-04-07 | — | — | US | disclosed |
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | OXER1, AOC3, OPRD1 | ALDH1A1 379/4885MAPT 3981/4885SMN1; SMN2 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.